Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127556271 | 12755627 | 1 | I | 20151230 | 20160905 | 20160916 | 20160916 | EXP | FR-TEVA-691854ROM | TEVA | 72.87 | YR | F | Y | 66.00000 | KG | 20160916 | OT | FR | FR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127556271 | 12755627 | 1 | PS | DOXORUBICINE TEVA | DOXORUBICIN | 1 | Intravenous drip | 4TH COURSE OF R-CHOP PROTOCOL (RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE) | 63097 | 81 | MG | ||||||||
127556271 | 12755627 | 2 | SS | METHOTREXATE. | METHOTREXATE | 1 | Intrathecal | U | 0 | 15 | MG | ||||||||
127556271 | 12755627 | 3 | SS | MABTHERA | RITUXIMAB | 1 | Subcutaneous | 4TH COURSE OF R-CHOP PROTOCOL (RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE) | 0 | 1400 | MG | ||||||||
127556271 | 12755627 | 4 | SS | ENDOXAN | CYCLOPHOSPHAMIDE | 1 | Intravenous drip | 4TH COURSE OF R-CHOP PROTOCOL (RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE) | 0 | 1220 | MG | ||||||||
127556271 | 12755627 | 5 | SS | VINCRISTINE HOSPIRA | VINCRISTINE | 1 | Intravenous drip | 4TH COURSE OF R-CHOP PROTOCOL (RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE) | 0 | 2 | MG | ||||||||
127556271 | 12755627 | 6 | SS | CORTANCYL | PREDNISONE | 1 | Oral | 4TH COURSE OF R-CHOP PROTOCOL (RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE) | D | 0 | 100 | MG | |||||||
127556271 | 12755627 | 7 | SS | METHYLPREDNISOLONE MYLAN | METHYLPREDNISOLONE | 1 | Intravenous drip | 0 | 80 | MG | |||||||||
127556271 | 12755627 | 8 | C | POLARAMINE | DEXCHLORPHENIRAMINE MALEATE | 1 | Intravenous (not otherwise specified) | 0 | 5 | MG | |||||||||
127556271 | 12755627 | 9 | C | Paracetamol | ACETAMINOPHEN | 1 | Intravenous drip | 0 | 500 | MG | |||||||||
127556271 | 12755627 | 10 | C | ONDANSETRON ACCORD 2 mg/ml | ONDANSETRON | 1 | Intravenous drip | 0 | 8 | MG | SOLUTION FOR INJECTION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127556271 | 12755627 | 1 | B-cell lymphoma |
127556271 | 12755627 | 2 | B-cell lymphoma |
127556271 | 12755627 | 3 | B-cell lymphoma |
127556271 | 12755627 | 4 | B-cell lymphoma |
127556271 | 12755627 | 5 | B-cell lymphoma |
127556271 | 12755627 | 6 | B-cell lymphoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127556271 | 12755627 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127556271 | 12755627 | Acute prerenal failure | |
127556271 | 12755627 | Campylobacter gastroenteritis | |
127556271 | 12755627 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127556271 | 12755627 | 1 | 20151221 | 0 | ||
127556271 | 12755627 | 2 | 20151221 | 0 | ||
127556271 | 12755627 | 3 | 20151221 | 0 | ||
127556271 | 12755627 | 4 | 20151221 | 0 | ||
127556271 | 12755627 | 5 | 20151221 | 0 | ||
127556271 | 12755627 | 6 | 20151222 | 20151225 | 0 | |
127556271 | 12755627 | 7 | 20151221 | 0 | ||
127556271 | 12755627 | 8 | 20151221 | 0 | ||
127556271 | 12755627 | 9 | 20151221 | 0 | ||
127556271 | 12755627 | 10 | 20151221 | 0 |